title: The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs.
abstract: A series of biodegradable amphiphilic block copolymers with controlled composition and relatively low polydispersity index were synthesized from monomethoxy polyethylene glycol (mPEG-OH, 5 kDa) via organocatalytic ring opening polymerization of aliphatic cyclic carbonate monomers - trimethylene carbonate (TMC) or cholesteryl 2-(5-methyl-2-oxo-1,3-dioxane-5-carboxyloyloxy)ethyl carbamate (MTC-Chol) or a copolymer of both the monomers (TMC and MTC-Chol): mPEG(113)-b-PTMC(67), mPEG(113)-b-P(MTC-Chol(11)) and mPEG(113)-b-P(MTC-Chol(x)-co-TMC(y))(x+y). These well-defined polymers were employed to study the role of molecular weight and composition of the hydrophobic block of the polymers in loading paclitaxel (PTX), an extremely hydrophobic anticancer drug with rigid structure and strong tendency of self-association to form long fibers. The PTX-loaded micelles were fabricated by simple self-assembly without sonication or homogenization procedures. The results demonstrated that the presence of both MTC-Chol and TMC in the hydrophobic block significantly increased PTX loading levels, and the micelles formed from the polymer with the optimized composition (i.e. mPEG(113)-b-P(MTC-Chol(11)-co-TMC(30))) were in nanosize (36 nm) with narrow size distribution (PDI: 0.07) and high PTX loading capacity (15 wt.%). In vitro treatment of human liver hepatocellular carcinoma HepG2 cells with blank micelles showed that these polymeric carriers were non-cytotoxic with cell viability greater than 90% at ~2400 mg/L. Importantly, PTX-loaded micelles were able to kill cancer cells much more effectively compared to free PTX. In addition, these nanocarriers also possessed exceptional kinetic stability. The results from non-invasive near-infrared fluorescence (NIRF) imaging studies showed that these micelles allowed effective passive targeting, and were preferably accumulated in tumor tissue with limited distribution to healthy organs.
authors.affiliation: Institute of Bioengineering and Nanotechnology, The Nanos, Singapore 138669, Singapore.
authors.forename: Ashlynn L Z
authors.initials: AL
authors.lastname: Lee
authors.forename: Shrinivas
authors.initials: S
authors.lastname: Venkataraman
authors.forename: Syamilah B M
authors.initials: SB
authors.lastname: Sirat
authors.forename: Shujun
authors.initials: S
authors.lastname: Gao
authors.forename: James L
authors.initials: JL
authors.lastname: Hedrick
authors.forename: Yi Yan
authors.initials: YY
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001673:Biodegradation, Environmental; D045744:Cell Line, Tumor; D002470:Cell Survival; D002784:Cholesterol / Q000737:chemistry*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007700:Kinetics; D008823:Micelles; D036103:Nanotechnology / Q000379:methods; D017239:Paclitaxel / Q000494:pharmacology; D011076:Polycarboxylate Cement / Q000737:chemistry; D011108:Polymers / Q000737:chemistry*; D019265:Spectroscopy, Near-Infrared / Q000379:methods; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008823:Micelles; D011076:Polycarboxylate Cement; D011108:Polymers; C005506:polycarbonate; D002784:Cholesterol; D017239:Paclitaxel